At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 75 enrolled
Drug / intervention
Lansoprazole Tablet +4 moredrug
Likely dose
Lansoprazole Tablet 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Placebo-Controlled Trial of BID Lansoprazole in Isolated Chronic Post Nasal Drip
In Brief
A Phase 3 clinical trial evaluating Lansoprazole Tablet, PH and impedence testing, and 3 other interventions for Larynx Disease. Completed, enrolled 75 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether aggressive acid suppression with Lansoprazole is effective in the treatment of post nasal drip, and also assess the predictors of response based on clinical and physiologic parameters.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLarynx Disease
CountriesUnited States
CollaboratorsTAP Pharmaceutical Products Inc.
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2006
Enrollment StartAug 2006
Primary CompletionDec 2008
TodayJul 2026
First PostedJun 9, 2006
Enrollment StartAug 1, 2006
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 20.1 years ago
Interventions
Lansoprazole Tabletdrug
40 mg bid x 16 weeks
PH and impedence testingprocedure
24 hour ph monitoring
manometryprocedure
done prior to pH probe to measure length of esophagus
lansoprazoledrug
40mg bid
placebodrug
one tablet bid